Journal
PHARMACEUTICAL RESEARCH
Volume 28, Issue 11, Pages 2669-2679Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-011-0476-8
Keywords
ischemia-reperfusion injury; metabolic disorders; neurodegenerative diseases; oxidative stress; Szeto-Schiller peptides
Ask authors/readers for more resources
Mitochondrial oxidative stress and dysfunction have been implicated in the aging process and in numerous chronic diseases. The need for therapies that can protect and/or improve mitochondrial function is obvious. However, the development of mitoprotective drugs has been hampered by a number of challenges, and there are at present no approved therapies for mitochondrial dysfunction. This article describes the original discovery, preclinical development, and clinical development of a novel class of small peptide molecules that selectively target the inner mitochondrial membrane and protect mitochondrial function. These compounds have the potential to be a paradigm-shifting approach to the treatment of mitochondrial dysfunction, which underlies many common diseases, including cardiorenal, neurologic, and metabolic disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available